Branch Retinal Vein Occlusion
Conditions
Interventions
Treatment group: 19 subjects with acute Branch Retinal Vein Occlusion (BRVO) and edeme that initiated between 0 and 6 months. The medication Ranibizumabe will be injected monthly within the vitreous a
Drug
H34.8
Sponsors
Universidade Federal do Espirito Santo
Universidade Federal do Espirito Santo
Eligibility
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Patients with Branck Retinal Venous occlusion (BRVO) with acute edema that started between 0 and 6 months; visual acuity between 20/40 and 20/400; Central foveal thickness greater than 250 microns , measured in optical coherence tomography (OCT); Age of 18 years or more; Subjects who agreed and signed an informed consent form.
Exclusion criteria
Exclusion criteria: Concomitant Conditions in the study eye that can, in the opinion of investigator, hinder the improvement of visual acuity with the proposed treatment; Opacities of ocular environment; Active intraocular inflammation (inflammation trace degree or above) in any eye; Any active infection (eg conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis.) In either eye; Previous history of uveitis in either eye; Structural damage in the macula in one of the macula center diameter disc in the study eye, which can prevent improvement in visual acuity after resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, scar (s) by laser or hard exudates arranged in the plate; Eye diseases in the study eye that can confuse the interpretation of the study results, compromising visual acuity or require medical or surgical intervention during the period of 6 months of the study, including retinal detachment, macular hole or choroidal neovascularization of any cause (eg macular disease related to age, ocular histoplasmosis or pathological myopia.); Glaucoma not controlled in the study eye (according to the investigator's judgment); Retinal neovascularization in the eye of the study; Previous episode of retinal vein occlusion in the study eye; afferent pupillary defect.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| absolute deviation (MD), measured by dual frequency perimetry (FDT) | — |
Secondary
| Measure | Time frame |
|---|---|
| Central retinal thickness as measured by OCT examination; Numbers of statistically significant areas P <5% in the total difference (total deviation) measured by FDT examination; Incidence of adverse events. | — |
Countries
Brazil
Contacts
Public ContactAlexandre ;alexandre Pinheiro;pinheiro
Universidade Federal do Espirito Santo;Universidade Federal do Espirito Santo
Outcome results
None listed